X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Wockhardt with JUBILANT LIFE SCIENCES - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

WOCKHARDT LTD. vs JUBILANT LIFE SCIENCES - Comparison Results

WOCKHARDT LTD.    Change

Wockhardt is one of the leading domestic pharmaceutical companies with strong presence in the lifestyle segment and a growing focus on biotechnology. While the company made a string of acquisitions in the past namely 'Esparma GmbH' in Germany, 'Pinew... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    WOCKHARDT LTD. JUBILANT LIFE SCIENCES WOCKHARDT LTD./
JUBILANT LIFE SCIENCES
 
P/E (TTM) x -23.9 17.2 - View Chart
P/BV x 2.4 4.5 53.5% View Chart
Dividend Yield % 0.0 0.4 0.4%  

Financials

 WOCKHARDT LTD.   JUBILANT LIFE SCIENCES
EQUITY SHARE DATA
    WOCKHARDT LTD.
Mar-18
JUBILANT LIFE SCIENCES
Mar-14
WOCKHARDT LTD./
JUBILANT LIFE SCIENCES
5-Yr Chart
Click to enlarge
High Rs1,012187 541.8%   
Low Rs53265 816.4%   
Sales per share (Unadj.) Rs355.9364.3 97.7%  
Earnings per share (Unadj.) Rs-60.36.8 -880.5%  
Cash flow per share (Unadj.) Rs-46.824.5 -190.9%  
Dividends per share (Unadj.) Rs0.013.00 0.3%  
Dividend yield (eoy) %02.4 0.1%  
Book value per share (Unadj.) Rs257.8164.9 156.3%  
Shares outstanding (eoy) m110.63159.28 69.5%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.20.3 627.4%   
Avg P/E ratio x-12.818.4 -69.6%  
P/CF ratio (eoy) x-16.55.1 -321.0%  
Price / Book Value ratio x3.00.8 391.9%  
Dividend payout %043.8 -0.0%   
Avg Mkt Cap Rs m85,37920,061 425.6%   
No. of employees `0006.36.2 101.1%   
Total wages/salary Rs m9,37111,052 84.8%   
Avg. sales/employee Rs Th6,295.09,383.0 67.1%   
Avg. wages/employee Rs Th1,498.31,786.9 83.9%   
Avg. net profit/employee Rs Th-1,066.3176.3 -604.8%   
INCOME DATA
Net Sales Rs m39,36958,034 67.8%  
Other income Rs m1,202191 630.8%   
Total revenues Rs m40,57158,224 69.7%   
Gross profit Rs m185,786 0.3%  
Depreciation Rs m1,4952,812 53.2%   
Interest Rs m2,5553,237 78.9%   
Profit before tax Rs m-2,830-72 3,924.5%   
Minority Interest Rs m0-286 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-3,5822,145 -167.0%   
Tax Rs m257696 36.9%   
Profit after tax Rs m-6,6691,090 -611.6%  
Gross profit margin %010.0 0.5%  
Effective tax rate %-9.1-965.9 0.9%   
Net profit margin %-16.91.9 -901.5%  
BALANCE SHEET DATA
Current assets Rs m33,79629,280 115.4%   
Current liabilities Rs m26,91738,912 69.2%   
Net working cap to sales %17.5-16.6 -105.3%  
Current ratio x1.30.8 166.9%  
Inventory Days Days7984 94.0%  
Debtors Days Days8951 176.1%  
Net fixed assets Rs m39,66455,712 71.2%   
Share capital Rs m553155 358.1%   
"Free" reserves Rs m27,96820,968 133.4%   
Net worth Rs m28,52226,265 108.6%   
Long term debt Rs m21,73117,169 126.6%   
Total assets Rs m81,62088,606 92.1%  
Interest coverage x-0.11.0 -11.0%   
Debt to equity ratio x0.80.7 116.6%  
Sales to assets ratio x0.50.7 73.6%   
Return on assets %-5.04.9 -103.2%  
Return on equity %-23.44.2 -563.2%  
Return on capital %-7.711.6 -66.3%  
Exports to sales %037.8 0.0%   
Imports to sales %016.5 0.0%   
Exports (fob) Rs mNA21,933 0.0%   
Imports (cif) Rs mNA9,567 0.0%   
Fx inflow Rs m9,80722,004 44.6%   
Fx outflow Rs m1,78911,749 15.2%   
Net fx Rs m8,01910,255 78.2%   
CASH FLOW
From Operations Rs m6848,026 8.5%  
From Investments Rs m6,302-1,744 -361.3%  
From Financial Activity Rs m-7,695-4,447 173.0%  
Net Cashflow Rs m-6641,834 -36.2%  

Share Holding

Indian Promoters % 74.5 45.6 163.4%  
Foreign collaborators % 0.0 3.5 -  
Indian inst/Mut Fund % 2.3 8.7 26.4%  
FIIs % 7.7 21.2 36.3%  
ADR/GDR % 0.1 0.0 -  
Free float % 15.4 21.1 73.0%  
Shareholders   67,757 23,815 284.5%  
Pledged promoter(s) holding % 0.0 15.9 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare WOCKHARDT LTD. With:   TTK HEALTHCARE  ALEMBIC LTD  WYETH LTD  AJANTA PHARMA  SUVEN LIFE  

Compare WOCKHARDT LTD. With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 170 Points Lower, Realty and FMCG Stocks Witness Selling(Closing)

After opening the day on a positive note, share markets in India witnessed volatile trading activity and ended in red.

Related Views on News

WOCKHARDT LTD. Announces Quarterly Results (1QFY19); Net Profit Down 81.4% (Quarterly Result Update)

Aug 6, 2018 | Updated on Aug 6, 2018

For the quarter ended June 2018, WOCKHARDT LTD. has posted a net profit of Rs 862 m (down 81.4% YoY). Sales on the other hand came in at Rs 10 bn (up 13.1% YoY). Read on for a complete analysis of WOCKHARDT LTD.'s quarterly results.

JUBILANT LIFE SCIENCES Announces Quarterly Results (1QFY19); Net Profit Up 39.4% (Quarterly Result Update)

Jul 31, 2018 | Updated on Jul 31, 2018

For the quarter ended June 2018, JUBILANT LIFE SCIENCES has posted a net profit of Rs 2 bn (up 39.4% YoY). Sales on the other hand came in at Rs 21 bn (up 30.2% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

Is It the Right Time to Buy Pharma Stocks Now?(The 5 Minute Wrapup)

Sep 12, 2018

Is the pharma sector poised for a comeback? Is the worst over? I believe so.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

The Secret Of Mirae Asset India Equity Fund's Increasing Popularity(Outside View)

Sep 7, 2018

The prudent investment strategies followed at the fund house has helped Mirae Asset India Equity Fund earn a tag of being a consistent performer, which is in turn gaining popularity among investors.

Should You Be Worried About the Rising Dollar?(Chart Of The Day)

Sep 7, 2018

While the rupee has deprecated by about 5% annually since 1990 against the dollar, the BSE Sensex has returned 14% annually in the same period.

Revenge of the Ratings Agencies(Vivek Kaul's Diary)

Sep 7, 2018

Do you remember when ratings agencies ruled financial markets? Nick explains why he thinks it's time to prepare yourselves for a comeback of the ratings agencies.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

WOCKHARDT LTD. SHARE PRICE


Sep 19, 2018 (Close)

TRACK WOCKHARDT LTD.

  • Track your investment in WOCKHARDT LTD. with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON WOCKHARDT LTD.

WOCKHARDT LTD. - TTK HEALTHCARE COMPARISON

COMPARE WOCKHARDT LTD. WITH

MARKET STATS